Metsera超长效GLP-1 MET-097 i在中期试验中表现出色

2025-09-30 04:59

Metsera's (NASDAQ:MTSR) MET-097i, a long-acting GLP-1 medicine for obesity that could be dosed as infrequently as once a month, demonstrated significant weight loss in phase 2b.
In VESPER-1, after 28 weekly injections, top-line data showed a mean placebo-subtracted weight loss of up to 14.1% at 1.2mg, the highest dose tested.
An interim analysis for tolerability was conducted for the other study, VESPER-3, with results showing that after 12 weekly doses, there was a minimal diarrhea signal and a risk difference from placebo of 13% nausea and 11% vomiting following two titration steps. VESPER-3 is ongoing and will evaluate the efficacy and tolerability of monthly doses over 28 weeks.
As a result of the positive data, Metsera said it would advance MET-097i into phase 3 by the end of 2025.
The company added that VESPER-3 topline monthly dosing data is expected by year end or early 2026. Another phase 2b trial, VESPER-2, is evaluating MET-097i in type 2 diabetes, with topline data projected in early 2026.
The new data comes just a week after Pfizer (PFE) announced a $4.9B deal to acquire Metsera.

More on Metsera